Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation

Bone Marrow Transplant. 2022 Feb;57(2):282-285. doi: 10.1038/s41409-021-01507-3. Epub 2021 Oct 28.

Authors

Rodrigo Martino¹, Irene García-Cadenas², Albert Esquirol²

Affiliations

¹ Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau and Jose Carreras Leukemia Research Institute, Autonomous University of Barcelona, Barcelona, Spain. rmartino@santpau.cat.
² Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau and Jose Carreras Leukemia Research Institute, Autonomous University of Barcelona, Barcelona, Spain.

No abstract available

Publication types

Letter

MeSH terms

ABO Blood-Group System
Antibodies, Monoclonal
Blood Group Incompatibility
Hemagglutinins
Hematopoietic Stem Cell Transplantation*
Humans
Red-Cell Aplasia, Pure* / drug therapy
Red-Cell Aplasia, Pure* / etiology
Transplantation, Homologous

Substances

ABO Blood-Group System
Antibodies, Monoclonal
Hemagglutinins
daratumumab